On Friday, the India’s largest drug maker Sun Pharmaceutical Industries said that there is an expectation that in 2019 the revenue to come in short of analysts’ expectation due t the pricing pressure in the main market, the United States. Due to thecopycat drugthere’s an increment in the competition and pricing inspection in the world …